UK asks: which prescription drugs are least likely to be falsified?
This article was originally published in Scrip
Executive Summary
Which prescription medicines are least likely to be falsified, and which non-prescription drugs are most at risk? That's what the UK regulator, the MHRA, would like to know as it prepares to draw up its proposed "black" and "white" lists of products that in future either should or should not carry the "safety feature" required by the EU falsified medicines Directive (FMD).
You may also be interested in...
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
EU Countries Offered Funding To Contribute to African Regulatory Strengthening
Training projects are intended to strengthen the African regulatory environment, boost the capacity of the African Medicines Agency, facilitate regulatory reliance, and increase joint new drug assessments.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.